Background. Peroxisome proliferator-activated receptor (PPAR)-g may counteract tissue fibrosis via its anti-inflammatory actions, while hypoxia, a new pro-fibrotic factor, reportedly modifies PPAR-g expression. However, the effects of hypoxia on the expression and anti-inflammatory actions of PPAR-g have yet remained to be clarified in renal tubular cells. Methods. Confluent human proximal rena...

Sambandam, Nandakumar, Dominique Morabito, Cory Wagg, Brian N. Finck, Daniel P. Kelly, and Gary D. Lopaschuk. Chronic activation of PPAR is detrimental to cardiac recovery after ischemia. Am J Physiol Heart Circ Physiol 290: H87–H95, 2006. First published September 9, 2005; doi:10.1152/ajpheart.00285.2005.— High fatty acid oxidation (FAO) rates contribute to ischemia-reperfusion injury of the m...

The nuclear receptor peroxisome proliferator-activated receptor (PPAR) is activated by a diverse group of acidic ligands, including many peroxisome proliferator chemicals present in the environment. Janus tyrosine kinase-signal transducer and activator of transcription (JAK-STAT) signaling is activated by multiple cytokines and hormones and leads to the translocation of dimerized STAT proteins ...

The biology of Peroxisome proliferator-activated receptor (PPAR) alpha (α) and gamma (γ) has been intensely scrutinized for the last 20 years and the clinical use of both PPAR-α (fibrates) and PPAR-γ (thiazolididiones) agonists has led to the understanding of their key role in the treatment of hypertriglyceridemia and type 2 diabetes mellitus [1, 2]. In contrast, the understanding of PPAR delta...

In recent years, the study of the peroxisome proliferators activated receptor gamma (PPAR-gamma) as a potential target for cancer prevention and therapy has gained a strong interest. However, the overall biological significance of PPAR-gamma in cancer development and progression is still controversial. While many reports documented antiproliferative effects in human cancer cell and animal model...

The thiazolidinedione (TZD) class of peroxisome proliferator-activated receptor (PPAR) ligands, known for their ability to induce adipocyte differentiation and increase insulin sensitivity, also exhibits anticancer properties. Currently, TZDs are being tested in clinical trials for treatment of human cancers expressing high levels of PPAR because it is assumed that activation of PPAR mediates t...

Fatty acid metabolism is transcriptionally regulated by two reciprocal systems: peroxisome proliferator-activated receptor (PPAR) controls fatty acid degradation, whereas sterol regulatory element-binding protein-1c activated by liver X receptor (LXR) regulates fatty acid synthesis. To explore potential interactions between LXR and PPAR, the effect of LXR activation on PPAR signaling was invest...

Recent studies have found that cyclooxygenase-2 (COX-2) protein expression was low and inducible with cytokines in prostate cancer cells (in the absence of serum) and that, in contrast, COX-2 expression was high in normal prostate epithelial cells (EC). Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) was expressed at high levels in the prostate cancer cell line PC-3 but not in ECs...

Fatty acid translocase (FAT)/CD36 is a glycoprotein involved in multiple membrane functions including uptake of long-chain fatty acids and oxidized low density lipoprotein. In mice, expression of the gene is regulated by peroxisome proliferator-activated receptor (PPAR) in the liver and by PPAR in the adipose tissues (Motojima, K., Passilly, P. P., Peters, J. M., Gonzalez, F. J., and Latruffe, ...

Pulmonary fibrosis is characterized by alterations in fibroblast phenotypes resulting in excessive extracellular matrix accumulation and anatomic remodeling. Current therapies for this condition are largely ineffective. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a member of the nuclear hormone receptor superfamily, the activation of which produces a number of biological ef...